Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc (KPTI) is a leader in developing novel cancer therapies through its pioneering research in nuclear export inhibition. This page provides investors and healthcare professionals with verified updates on clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time announcements about XPOVIO (selinexor) developments, pipeline progress across multiple oncology indications, and global commercialization efforts. Our curated collection includes press releases on FDA approvals, clinical trial results, partnership agreements, and financial disclosures.
Key updates cover therapeutic innovations in multiple myeloma, myelofibrosis, and other high-need cancers. Stay informed about Karyopharm's scientific leadership through objective reporting of peer-reviewed data and market expansion activities. Bookmark this page for direct access to primary source materials that drive informed analysis.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 150,600 shares to 15 new employees, effective March 31, 2021. The options have an exercise price of $10.52, aligning with the closing price on the grant date. These options will vest over four years, with an initial 25% vesting after one year, followed by monthly vesting. Additionally, the options may become fully exercisable upon termination for 'good reason' or without 'cause' after a 'change in control' event. This move is expected to attract talent as the company advances its cancer therapies.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that the European Commission has granted conditional marketing authorization for NEXPOVIO (selinexor) in combination with dexamethasone for treating adult patients with heavily pretreated multiple myeloma. This breakthrough therapy targets patients who have undergone at least four prior treatments and are refractory to multiple other therapies. The authorization is based on positive results from the Phase 2b STORM study, which showed a 26% overall response rate. The drug is the first nuclear export inhibitor approved in Europe and is set for initial availability through a Named Patient Program.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options to 11 new employees. An aggregate of 93,600 shares is available for purchase at an exercise price of $13.82 per share, corresponding to the closing price on February 26, 2021. These options vest over four years, with 25% vesting after one year and subsequent monthly vesting. The options will fully vest upon certain termination scenarios within a year of a 'change in control event.'
Karyopharm Therapeutics (Nasdaq: KPTI), a company focused on innovative cancer therapies, will have CEO Michael Kauffman participate in two virtual investor conferences. The SVB Leerink 10th Annual Global Healthcare Conference is scheduled for February 24, 2021, at 1:00 PM ET, while the Barclays Global Healthcare Conference will take place on March 9, 2021, at 9:10 AM ET. Live webcasts will be available on Karyopharm's website, with replays accessible for 30 days post-event.
Karyopharm Therapeutics (KPTI) reported fourth quarter 2020 net product revenue of $20.2 million, a 5% decline from Q3 2020, attributed to COVID-19 impacts and increased competition. The company achieved FDA approval for XPOVIO in additional oncology indications, expanding its market potential. Total revenue for 2020 was $76.2 million, a significant increase from $30.5 million in 2019. However, the net loss for Q4 was $43.4 million, an improvement from Q4 2019. Karyopharm maintains a strong cash position of $276.7 million as it looks ahead to 2021.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) will announce its fourth quarter and full year 2020 financial results on February 11, 2021. A conference call will be hosted by the management team at 8:30 a.m. ET to discuss these results and provide company updates. Karyopharm specializes in innovative cancer therapies, including its lead drug, XPOVIO® (selinexor), which has multiple U.S. approvals for various hematologic malignancies. A Marketing Authorization Application for selinexor is also under review by the European Medicines Agency.
Karyopharm Therapeutics (Nasdaq: KPTI) announced that Promedico Ltd. has received approval from the Israeli Ministry of Health for XPOVIO® (selinexor) to treat multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The approved use includes XPOVIO combined with dexamethasone for adult patients with relapsed refractory multiple myeloma who have undergone at least three therapies and for those with relapsed or refractory DLBCL post two systemic therapies. Karyopharm anticipates further registration in Israel by Q2 2021 and awaits a European Commission decision on NEXPOVIO® by April 2021.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on February 1, 2021, that its Compensation Committee granted stock options for 165,500 shares to 31 new employees as an inducement for joining the company. The stock options have an exercise price of $15.23, equal to the closing stock price on January 29, 2021, and will vest over four years. They will be immediately exercisable under certain conditions related to employment termination. KPTI develops novel cancer therapies, with its lead drug, XPOVIO®, approved in various hematologic malignancy indications.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that the European Medicines Agency's CHMP has issued a positive opinion recommending conditional approval for NEXPOVIO® (selinexor) in combination with dexamethasone for treating multiple myeloma in patients with extensive prior therapy. This recommendation is a critical step toward a final decision by the European Commission, expected by April 2021. The MAA is supported by the Phase 2b STORM study, showing a 26% overall response rate in heavily pretreated patients. Karyopharm plans to expand its regulatory filing based on additional study data.
Karyopharm Therapeutics (Nasdaq: KPTI) reported preliminary unaudited revenue estimates for Q4 and full year 2020, expecting total revenues of $35-$36 million for the fourth quarter and $108-$109 million for the year. Net product sales for XPOVIO are estimated between $20-$20.5 million for Q4 and $76-$76.5 million for the year. A decline in sales was noted, attributed to COVID-19 impacts and increased competition. The company entered a distribution agreement for XPOVIO in Canada, generating $15 million in license revenue. The cash position increased to $277 million by year-end 2020.
